Resumen
BACKGROUND: We have previously reported important strain differences in response to SU5416 (SU, a vascular endothelial growth factor receptor 2 inhibitor) in rats and have identified a specific colony of Sprague-Dawley rats that are hyperresponsive (SDHR) to SU alone and develop severe pulmonary arterial hypertension (PAH) with a single injection of SU, even in the absence of hypoxia. Interestingly, SDHR rats exhibit incomplete penetrance of the severe PAH phenotype with an “all-or- none” response to SU alone, which provides a unique opportunity to assess the influence of female sex and sex hormones on susceptibility to PAH after endothelial injury in a genetically prone model. METHODS AND RESULTS: SDHR rats were injected with SU (20 mg/kg SC) and, in the absence of hypoxia, 72% of male but only 27% of female rats developed severe PAH at 7 weeks, which was associated with persistent endothelial cell apoptosis. This sex difference in susceptibility for severe PAH was abolished by ovariectomy. Estradiol replacement, beginning 2 days before SU (prevention), inhibited lung endothelial cell apoptosis and completely abrogated severe PAH phenotype in both male and ovariectomized female rats, while progesterone was only protective in ovariectomized female rats. In contrast, delayed treatment of SDHR rats with established PAH with estradiol or progesterone (initiated at 4 weeks post-SU) failed to reduce lung endothelial cell apoptosis or improve PAH phenotype. CONCLUSIONS: Female sex hormones markedly reduced susceptibility for the severe PAH phenotype in response to SU alone in a hyperresponsive rat strain by abolishing SU-induced endothelial cell apoptosis, but did not reverse severe PAH in established disease.
Idioma original | English |
---|---|
Número de artículo | e019488 |
Publicación | Journal of the American Heart Association |
Volumen | 10 |
N.º | 15 |
DOI | |
Estado | Published - 2021 |
Nota bibliográfica
Funding Information:This research was supported by a grant from Actelion Pharmaceuticals US, Inc, and an ENTELLIGENCE Young Investigator Program to K.R.C. This study was funded by a Catalyst grant from the Canadian Institute of Health Research to D.J.S. and K.R.C. (Funding reference no. SVB-145555). This work was supported by a Foundation Award from the Canadian Institutes for Health Research (FDN – 143291) to DJS. K.R.C. is a recipient of scholar award from Canadian Vascular Network and Heart and Stroke Foundation of Canada.
Publisher Copyright:
© 2021 The Authors.
ASJC Scopus Subject Areas
- Cardiology and Cardiovascular Medicine
PubMed: MeSH publication types
- Comparative Study
- Journal Article
- Research Support, Non-U.S. Gov't